Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes

Research output: Contribution to journalReviewResearchpeer-review

  1. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Patients with prolonged effect of succinylcholine or mivacurium had novel mutations in the butyrylcholinesterase gene

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hypertension genetic risk score is associated with burden of coronary heart disease among patients referred for coronary angiography

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Unchanged mitochondrial phenotype, but accumulation of lipids in the myometrium in obese pregnant women

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ultralydsscanning af endometriet hos asymptomatiske postmenopausale kvinder

    Research output: Other contributionCommunication

  4. Placenta accreta: adherent placenta due to Asherman syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The aim of this study was to summarize current knowledge and provide perspectives on the relationships between human genetic variants, type 2 diabetes, antidiabetic treatment, and disease progression. Type 2 diabetes is a complex disease with clear-cut diagnostic criteria and treatment guidelines. Yet, the interindividual response to therapy and slope of disease progression varies markedly among patients with type 2 diabetes. Gene-gene, gene-environment, and gene-treatment interactions may explain some of the variation in disease progression. Several genetic variants have been suggested to be associated with response to antidiabetic drugs. Some are present in drug receptors or drug metabolizers (OCT genes, KCNJ11, ABCC8, and CYP2C9). Numerous type 2 diabetes risk variants have been identified, but genetic risk score models applying these variants have failed to identify 'disease progressors' among patients with diabetes. Although genetic risk scores are based on a few known loci and only explain a fraction of the heritability of type 2 diabetes, it seems that the genes responsible for the development of diabetes may not be the same driving disease progression after the diagnosis has been made. Pharmacogenetic interactions explain some of the interindividual variation in responses to antidiabetic treatment and may provide the foundation for future genotype-based treatment standards.

Original languageEnglish
JournalPharmacogenetics and Genomics
Issue number10
Pages (from-to)475-84
Number of pages10
Publication statusPublished - Oct 2015

    Research areas

  • Diabetes Mellitus, Type 2, Disease Progression, Humans, Hyperglycemia, Hypoglycemic Agents, Pharmacogenetics, Journal Article, Research Support, Non-U.S. Gov't, Review

ID: 51900938